Review finds cannabis may improve IBD symptoms but standardized treatment protocols are lacking
A review of cannabis for inflammatory bowel disease found evidence of improved UC and CD symptom scores and quality of life, but the lack of standardized preparations and doses prevents establishing treatment criteria.
Quick Facts
What This Study Found
Cannabis use was associated with improvement in ulcerative colitis and Crohn's disease symptom scores and quality of life across reviewed studies. THC and CBD showed relevant anti-inflammatory and antioxidant properties. However, no standardization exists for plant variety, route of administration, or dosing.
Key Numbers
No specific pooled effect sizes reported; the review synthesizes findings across multiple studies showing symptom score improvement.
How They Did This
Literature review searching PubMed/Medline, PMC, EMBASE, and Cochrane databases for studies on cannabis effects in ulcerative colitis and Crohn's disease.
Why This Research Matters
IBD affects millions worldwide and current treatments often have significant side effects. Understanding whether cannabis compounds could complement existing therapies is clinically relevant.
The Bigger Picture
Patient interest in cannabis for IBD is high, but the gap between preclinical anti-inflammatory evidence and standardized clinical application remains wide.
What This Study Doesn't Tell Us
No meta-analysis performed; wide heterogeneity in cannabis preparations studied; many studies have small samples; no standardized treatment protocols exist.
Questions This Raises
- ?Which cannabinoid ratios and delivery methods are optimal for IBD?
- ?Do anti-inflammatory effects translate to mucosal healing or just symptom relief?
Trust & Context
- Key Stat:
- Symptom improvement reported but no standardized treatment protocol can be established
- Evidence Grade:
- Narrative review of heterogeneous studies without meta-analysis; underlying evidence limited by lack of standardization.
- Study Age:
- Published in 2020.
- Original Title:
- Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.
- Published In:
- International journal of molecular sciences, 21(8) (2020)
- Authors:
- Carvalho, Antonelly Cassio Alves de, Souza, Gabriela Achete de, Marqui, Samylla Vaz de, Guiguer, Élen Landgraf, Araújo, Adriano Cressoni, Rubira, Claudio José, Goulart, Ricardo de Alvares, Flato, Uri Adrian Prync, Bueno, Patricia Cincotto Dos Santos, Buchaim, Rogério Leone, Barbalho, Sandra M
- Database ID:
- RTHC-02455
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat Crohn's disease or ulcerative colitis?
Reviewed studies showed symptom improvement and better quality of life scores, but the researchers emphasize they cannot establish treatment criteria due to wide variation in cannabis preparations, doses, and delivery methods across studies.
What anti-inflammatory effects does cannabis have for IBD?
Both THC and CBD have demonstrated anti-inflammatory and antioxidant properties in preclinical studies that are theoretically relevant to IBD. However, translating these properties into consistent clinical benefit requires more standardized research.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02455APA
Carvalho, Antonelly Cassio Alves de; Souza, Gabriela Achete de; Marqui, Samylla Vaz de; Guiguer, Élen Landgraf; Araújo, Adriano Cressoni; Rubira, Claudio José; Goulart, Ricardo de Alvares; Flato, Uri Adrian Prync; Bueno, Patricia Cincotto Dos Santos; Buchaim, Rogério Leone; Barbalho, Sandra M. (2020). Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.. International journal of molecular sciences, 21(8). https://doi.org/10.3390/ijms21082940
MLA
Carvalho, Antonelly Cassio Alves de, et al. "Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.." International journal of molecular sciences, 2020. https://doi.org/10.3390/ijms21082940
RethinkTHC
RethinkTHC Research Database. "Cannabis and Canabidinoids on the Inflammatory Bowel Disease..." RTHC-02455. Retrieved from https://rethinkthc.com/research/carvalho-2020-cannabis-and-canabidinoids-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.